New secondary results from the NeoCOAST-2 phase 2 trial in resectable stage IIA–IIIB NSCLC show 24-month event-free survival rates of 70.5%, 75.7% and 77.9% across three durvalumab combination arms (with oleclumab, monalizumab, and datopotamab deruxtecan respectively). Clearance of circulating tumour DNA by the third treatment cycle was most frequent in the datopotamab deruxtecan arm (72.5%) and was strongly associated with longer event-free survival, especially when combined with pathological complete response.
nature.com
· 2026-10-25
Researchers at Seoul National University, publishing in Nature Medicine, analyzed health data from over 4.5 million Korean adults divided into smokers and short- or long-term quitters. Former smokers who switched to daily vaping developed lung cancer at a rate 56 percent higher than those who quit all nicotine products, and had a 91 percent higher lung cancer death rate.
futurism.com
· 2026-10-16
Researchers analyzed bronchial tissue from a long-running UCLH bronchoscopy surveillance study tracking patients with preinvasive lung lesions, alongside several related UK cohorts, to examine immune changes as lesions progress toward invasive cancer. The work focused on identifying a regulatory T cell signaling axis present in preinvasive tissue that may influence whether lesions advance to high-grade disease or carcinoma, combining human tissue analysis with mouse model experiments.
nature.com
· 2026-10-07
A recent report by the American Association for Cancer Research reveals that 71% of cancer patients in the US now survive at least five years post-diagnosis, compared to 49% in the late 1970s. Notable improvements include lung cancer, where five-year survival rates have risen from 13% to 29%, and childhood leukemia, with survival rates for young patients increasing from 57% to 90%. These advances are attributed to better surgical methods, radiation therapy, and targeted medicines.
nature.com
· 2026-10-05
Researchers led by Conery et al., writing in Nature, report a strategy for treating lung cancers driven by mutated kinase enzymes that destroys the target protein entirely rather than merely inhibiting its activity. The approach is aimed at cancers that develop resistance to existing kinase inhibitors after acquiring mutations near the drug's binding site. Twenty-eight kinase inhibitors are already FDA-approved across nine molecular lung cancer subtypes, but many patients eventually relapse due to such resistance mutations.
nature.com
· 2026-09-29
Researchers led by Stanford computer scientist James Zou built a system called Virtual Biotech, using up to 37,000 AI agents modeled like departments of a biotech company, overseen by a 'chief scientific officer' agent. After analyzing thousands of past clinical trials, the AI swarm flagged an immune-dampening protein as a target and, with human guidance, proposed a candidate treatment for lung cancer, detailed in a new Science paper.
nature.com
· 2026-09-17
A retired NYPD officer treated for lung cancer linked to ground zero exposure describes losing multiple friends—construction workers, firefighters and police—to cancers and respiratory illness in the years after 9/11. The 25th anniversary ceremony at the World Trade Center will include a new moment of silence honoring those who died from post-exposure illnesses rather than the attacks themselves.
statnews.com
· 2026-09-11
Researchers report findings on biological markers that correlate with improved patient outcomes when immune-based therapies are used before and after surgery for lung cancer. The publication, appearing on Nature's platform, outlines how certain biomarkers may help predict which patients respond best to this perioperative treatment approach.
nature.com
· 2026-09-02
A week after its US approval for advanced pancreatic cancer, the drug daraxonrasib has shown early promise against non-small cell lung cancer, the most common form of the disease. In a small trial published in the New England Journal of Medicine, tumors shrank in over 30% of patients whose cancers carried mutations in RAS family proteins and who had already failed other treatments. A larger randomized trial comparing daraxonrasib to standard chemotherapy is now underway.
nature.com
· 2026-09-02
GoKawiil